HCW Biologics Inc. (NASDAQ: HCWB) announced the successful closing of an exclusive worldwide license agreement for its molecule HCW11-006, a promising fusion immunotherapeutic. The agreement includes a total upfront payment of $7 million, which consists of a $3.5 million cash payment and an additional $3.5 million in the form of a transferable equity interest in the licensee, Beijing Trimmune Biotech Co., Ltd. This strategic partnership is expected to enhance HCW Biologics' position in the biopharmaceutical market, particularly in the development of novel therapies for autoimmune diseases and cancer.

The license agreement allows Trimmune to initiate a Phase 1 clinical study in China, anticipated to begin in the first half of 2027. HCW Biologics retains a unique option to reclaim rights to the Americas territory after the completion of the Phase 1 trial, providing a significant strategic advantage. The deal also positions HCW Biologics to receive milestone payments and royalties on future sales of HCW11-006, further enhancing its revenue potential.

This development is a notable step for HCW Biologics as it continues to expand its portfolio of innovative therapies aimed at addressing significant unmet medical needs. The partnership with Trimmune, which is backed by substantial investment from CITIC Medical Fund and TigerYeah Capital Fund, underscores the confidence in the potential of HCW11-006 and the expertise of the team leading Trimmune. With this agreement, HCW Biologics is poised for growth and increased market presence in the competitive biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.